The China-based company shared findings for its integrated CGM and CKM diabetes management solution as well. It showcased the technology at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
SiBionics says its GS3 CGM and KS3 CKM devices demonstrated technical strengths and clinical relevance in real-world diabetes management. A feasibility study confirmed that the GS3 system met and exceeded integrated CGM (iCGM) standards, the company said.
iCGMs pair with insulin pumps to create automated insulin delivery systems. SiBionics earlier this year announced a partnership with PharmaSens to deliver a first-of-its-kind all-in-one insulin patch pump.
Company officials outlined how the system works in an interview with Drug Delivery Business News at the American Diabetes Association’s Scientific Sessions in Chicago in June.
SiBionics says the GS3 system demonstrated “exceptional performance,” the company said, particularly in the hypoglycemic range. The company says it surpassed iCGM requirements and reinforced its value in supporting clinical decision-making and patient self-management.
Additionally, the rise of interest in continuous ketone monitoring remains one to watch, as it remains an untapped market in diabetes management. Abbott is advancing its own dual monitor, with several pump partnerships already agreed ahead of regulatory approval. The two companies have a history as well, engaging in recent legal battles over CGM IP in Europe.
“As a rising leader in continuous monitoring technologies — and currently the only company worldwide to commercialize CKM — SiBionics has showcased its strong R&D capabilities and pioneering vision,” SiBionics said. “Looking ahead, the company will continue to expand its CXM portfolio, driving innovation and delivering precise, high-quality solutions to improve outcomes for people with diabetes globally.”
